Date Filed:
Monday, July 2, 2012
Settlement Amount:
$3,000,000,000
A settlement has been reached in a whistleblower class action lawsuit brought against GlaxoSmithKline who is accused of promoting some of its antidepressants for unapproved uses and failing to report safety data about a top diabetes drug and improper marketing of a half-dozen other drugs.
The settlement includes $1 billion in criminal fines and $2 billion in civil fines. $300 million of the settlement will go to states and other public health authorities. A portion of the civil fine will go to the contributing whistleblowers.
The case was originally filed in 2012 in the U.S. District Court for the District of Massachusetts.
